Park Jong Chul, Hahn Noah M
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
Clin Adv Hematol Oncol. 2014 Dec;12(12):838-45.
Despite high incidence rates and substantial financial burdens associated with the care of patients with bladder cancer, progress in bladder cancer management has been modest and no new therapeutic agents for bladder cancer have been approved over the past decades. Fortunately, a substantial improvement in our understanding of the biology of this disease has occurred owing to revolutionizing molecular analysis platforms and increased interest among physicians and scientists in bladder cancer. As a consequence, a number of promising novel therapeutic agents are in development and are expected to make their way into clinics in the near future. This review focuses on the unique aspects of current bladder cancer research that support the assertion that bladder cancer is a likely frontier for major advancements soon.
尽管膀胱癌患者的发病率很高，且护理负担沉重，但过去几十年来，膀胱癌治疗进展缓慢，没有新的治疗药物获批。幸运的是，由于分子分析平台的革新以及医生和科学家对膀胱癌的兴趣增加，我们对这种疾病生物学特性的认识有了显著提高。因此，一些有前景的新型治疗药物正在研发中，预计不久将进入临床应用。本综述重点关注当前膀胱癌研究的独特方面，这些方面支持了膀胱癌很可能很快成为重大进展前沿领域这一观点。
